Missouri AG Intensifies Kratom Scrutiny, Highlighting Urgent Need for Industry Compliance

Missouri AG Intensifies Kratom Scrutiny, Highlighting Urgent Need for Industry Compliance

Jefferson City, MO – The Missouri Attorney General's office, under Catherine Hanaway, has significantly expanded its statewide investigation into kratom manufacturers and retailers, reportedly now encompassing 22 businesses. This intensified scrutiny follows initial Civil Investigative Demands (CIDs) issued to several companies, signaling a growing concern over the safety, purity, and marketing practices of kratom products sold within the state.

What Happened: An Expanding Investigation

Attorney General Hanaway's office launched its investigation due to "troubling reports that consumers may be exposed to unapproved, unsafe, and deceptively marketed opioid-like drugs". The focus includes products containing mitragynine and 7-hydroxymitragynine (7-OH), powerful psychoactive compounds found in kratom, with particular concern for those where 7-OH levels "far exceed what occurs naturally in the plant". The CIDs, which act as subpoenas, demand various documents, including lab test results, research on health risks, and safety label information from the targeted businesses. This action underscores the AG's commitment to protecting consumers from potentially dangerous and misleading products in an unregulated market.

Why It Matters to Kratom Merchants and Consumers

This aggressive stance by the Missouri Attorney General carries significant implications for both kratom businesses and consumers. For merchants, it means heightened legal and regulatory risk. Businesses found in violation of consumer protection laws, particularly concerning product safety and deceptive marketing, could face severe penalties, including fines and operational restrictions. The investigation also highlights the precarious position of kratom in states without comprehensive regulatory frameworks.

For consumers, the investigation brings much-needed attention to product quality and safety concerns. The AG's office has voiced apprehension that Missourians are being sold "drug-like substances under the guise of harmless supplements, with no FDA approval, no safety testing, and in some cases no meaningful disclosure of what these products actually contain". This action aims to ensure transparency and accountability, protecting public health.

Compliance Implications and the Push for Regulation

The Missouri AG's investigation serves as a powerful catalyst for regulatory reform. Currently, Missouri lacks a comprehensive statewide regulatory framework for kratom, though local ordinances like Kansas City's have emerged, banning synthetic kratom and restricting natural kratom sales to adults 21 and older, requiring special licenses for sellers.

Several legislative efforts have sought to establish a "Kratom Consumer Protection Act" (KCPA) in Missouri (e.g., HB912, HB2700, SB504, HB1595). These proposed acts aim to set age limits (often 18 or 21), mandate clear labeling, prohibit adulterated or contaminated products, and cap the concentration of 7-OH (typically at 2% of the alkaloid composition). Some proposals even suggest requiring processors to be registered with the FDA, comply with Good Manufacturing Practices (GMPs), and maintain product liability insurance. The ongoing investigation may accelerate the passage of such legislation, providing a clearer operational landscape but also stricter compliance requirements for businesses. There are also active discussions in the Missouri Senate regarding bills to regulate kratom, limit 7-OH potency, and even schedule 7-OH as a Schedule I controlled substance when concentrated above a certain level.

What High-Risk Merchants Need to Know

For high-risk kratom merchants, the Missouri AG's actions underscore the critical importance of proactive and robust compliance measures:

1. Third-Party Lab Testing and COAs: Comprehensive third-party lab testing is non-negotiable. Every batch of kratom product must be tested for purity, potency (mitragynine and 7-OH content), and contaminants such as heavy metals, pathogens, and adulterants. Readily available Certificates of Analysis (COAs) for all products are essential for transparency and to demonstrate due diligence. These COAs should come from ISO-accredited laboratories.
2. Accurate and Transparent Labeling: Labels must accurately reflect the product's contents, including the precise amounts of mitragynine and 7-OH. Avoid any misleading claims about health benefits or therapeutic uses. Labels should also include clear serving size recommendations, warnings, and an age restriction notice, even where not explicitly mandated by state law.
3. Adherence to Best Practices (KCPA Principles): Even if a statewide KCPA is not yet enacted, merchants should proactively adopt its core principles. This includes prohibiting sales to minors, ensuring products are not adulterated or contaminated, and maintaining 7-OH levels within proposed limits (e.g., below 2% of total alkaloid content or as naturally occurring). Avoid synthetic alkaloids entirely.
4. No Deceptive Marketing: Refrain from marketing kratom as a "cure" or making unsubstantiated health claims. Marketing should be factual and not target minors or mimic candy.
5. Stay Informed on Local and State Legislation: The regulatory landscape for kratom is dynamic. Merchants must continuously monitor legislative developments at both the state and local levels in all operating jurisdictions.

The Missouri AG's expanded investigation serves as a stark reminder that in the absence of federal regulation, states will increasingly step in to address public health concerns related to kratom. For the kratom industry, embracing stringent self-regulation and advocating for sensible, science-backed legislation like the KCPA is paramount to ensuring long-term viability and consumer trust.